BioCryst Pharmaceuticals BCRX Accrued interest
Accrued interest at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's accrued interest.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's accrued interest?
- BioCryst Pharmaceuticals (BCRX) reported accrued interest of $771K in Q1 2026.
- How has BioCryst Pharmaceuticals's accrued interest changed year-over-year?
- BioCryst Pharmaceuticals's accrued interest decreased by 20.0% year-over-year, from $964K to $771K.
- What is the long-term trend for BioCryst Pharmaceuticals's accrued interest?
- Over 4 years (2020 to 2025), BioCryst Pharmaceuticals's accrued interest has grown at a -48.8% compound annual growth rate (CAGR), from $21.67M to $1.49M.
- What does accrued interest mean?
- Interest expense accrued but not yet paid on outstanding debt obligations, based on contractual interest rates and time elapsed.